Login to Your Account



Phase II trial of Vtv's GLP-1 receptor agonist shows reduced HbA1c

By Michael Fitzhugh
Staff Writer

Thursday, December 15, 2016

Vtv Therapeutics Inc. reported that TTP273 helped type 2 diabetics on stable doses of metformin achieve mean placebo-subtracted HbA1c differences of up to -0.86 percent during a phase II study.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription